Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients

This study is currently recruiting participants.

Study NCT00424606 Information provided by Hellenic Oncology Research Group

First Received: January 18, 2007 Last Updated: September 25, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	April 2013
Estimated Primary Completion Date:	April 2013 (Final data collection date for primary outcome measure)